Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

Kangji Medical (9997 HK): A Close Run Thing

Kangji Medical (9997 HK): A Closer Look At The Shareholder Register

Kangji Medical (9997 HK): TPG/QIA/Founder's Offer Is No Knockout

Kangji Medical (9997 HK): Q&A With The FA

Kangji Medical (9997 HK): Speedy Turnaround On Pre-Cons

Quiddity Advisors

Event-Driven

Hangzhou Kangji Medical Instrument Co., Ltd. / Event-Driven

Hangzhou Kangji Medical Instrument Co., Ltd. (9997 HK)

Hangzhou Kangji Medical Instrument Co., Ltd.

<ul>
<li>On the 12th August, <a href="https://www.smartkarma.com/entities/hangzhou-kangji-medical-instrument-co-ltd" target="_blank" data-smartkarma-citation="entities:28938:1" rel="noopener">Hangzhou Kangji Medical (9997 HK)</a> announced an Offer, by way of a Scheme, from a consortium led by TPG and Qatar Investment Authority, together with the founders.</li>
<li>The HK$9.25/share consideration price (declared final), was an lacklustre 9.9% premium to last close. But pitched around a four-year high. </li>
<li>
<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1013/2025101300039.pdf" target="_blank" rel="noopener">The Scheme Document is now out</a>, with a Court Meeting on the 10th November and expected payment around the 16th December - in line with my expectations.</li>
</ul>


On the 12th August, Hangzhou Kangji Medical (9997 HK) announced an Offer, by way of a Scheme, from a consortium led by TPG and Qatar Investment Authority, together with the founders.
The HK$9.25/share consideration price (declared final), was an lacklustre 9.9% premium to last close. But pitched around a four-year high. 

The Scheme Document is now out, with a Court Meeting on the 10th November and expected payment around the 16th December - in line with my expectations.


Kangji Medical (9997 HK): 10th Nov Shareholder Vote on Founders/TPG/QIA's Offer